Printer Friendly

Millipore Elects Professor Dr. Daniel Bellus to Board of Directors.

Business/Technology Editors

BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 17, 2000

Millipore Corporation (NYSE/MIL) announced today the election of Professor Dr. Daniel Bellus to the board of directors of the corporation effective March 10, 2000. Dr. Bellus is the global Head of Research, Division Additives, of Ciba Specialty Chemicals, Inc., and Chairman of the company's Corporate Research Council. He is also a professor at the Institute of Organic Chemistry at the University of Fribourg in Switzerland.

Dr. Bellus joined J.R. Geigy AG (which later became Ciba-Geigy and is now Novartis) as a Research Chemist in 1969. He subsequently held executive positions in the company's Central Research Laboratories, Agricultural Division and Pharmaceutical and Specialty Chemicals R&.

C. William Zadel, Millipore's Chairman, President and CEO, noted: &uot;We are very pleased that Dr. Belles has agreed to be part of the Millipore Board. His scientific expertise and credentials are outstanding, and are relevant to Millipore's R& initiatives. Since so much of our business is in Europe, Dr. Bellus's European insights and perspectives will also prove valuable. We look forward to working with him.&uot;

Bellus holds 48 patents and has written 90 scientific papers. He is also an advisory board member of various international scientific journals. His honors in the world of science and chemistry include honorary doctorates from several European universities. He is also a foreign fellow of the Japan Society for the Promotion of Science and a fellow of The Royal Society of Chemistry.

Dr. Bellus received his doctorate in chemistry from Slovak Technical University in Bratislava. He was a postdoctoral fellow at the Federal Institute of Technology (ETH) in Zurich, Switzerland. Dr. Bellus is a Swiss citizen and was born in 1938.

Dr. Bellus replaces Samuel C. Butler, who is retiring from the Millipore Board effective March 10, 2000.

Millipore is a multinational, high technology company that applies its purification technology to critical research and manufacturing applications in the biopharmaceutical and microelectronics industries.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 17, 2000
Previous Continues 50% Off Promotion-logs Record Unique Visitors On First Day.
Next Article:PRASARA's Customer Care Application Launches on Time Warner Cable of New York City System.

Related Articles
Agriculture and plant science. (Divisional Reports).
Tomasetti Group elects new chairman.
Primary Care.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters